Leveraging external data in the design and analysis of clinical trials in neuro-oncology

被引:0
|
作者
Rahman, Rifaquat [1 ]
Ventz, Steffen [2 ]
McDunn, Jon [4 ]
Louv, Bill [4 ]
Reyes-Rivera, Irmarie [5 ]
Polley, Mei-Yin C. [6 ]
Merchant, Fahar [7 ]
Abrey, Lauren E. [8 ]
Allen, Joshua E. [9 ]
Aguilar, Laura K. [10 ]
Aguilar-Cordova, Estuardo [10 ]
Arons, David [11 ]
Tanner, Kirk [11 ]
Bagley, Stephen [12 ]
Khasraw, Mustafa [13 ]
Cloughesy, Timothy [14 ]
Wen, Patrick Y. [3 ]
Alexander, Brian M. [1 ,15 ]
Trippa, Lorenzo [2 ]
Roche, F. Hoffmann-La
Aguilar-Cordova, E.
Tanner, K.
机构
[1] Harvard Med Sch, Dept Radiat Oncol, Dana Farber Brigham & Womens Canc Ctr, Boston, MA 02115 USA
[2] Harvard TH Chan Sch Publ Hlth, Dept Data Sci, Boston, MA USA
[3] Harvard TH Chan Sch Publ Hlth, Dana Farber Canc Inst, Ctr Neurooncol, Boston, MA USA
[4] Project Data Sphere, Morrisville, NC USA
[5] F Hoffmann La Roche, Basel, Switzerland
[6] Univ Chicago, Dept Publ Hlth Sci, Chicago, IL 60637 USA
[7] MedicennaTherapeut, Toronto, ON, Canada
[8] Novartis, Basel, Switzerland
[9] Chimerix, Durham, NC USA
[10] Candel Therapeut, Needham, MA USA
[11] Natl BrainTumor Soc, Newton, MA USA
[12] Univ Penn, Perelman Sch Med, Div Hematol & Oncol, Philadelphia, PA 19104 USA
[13] Duke Univ, Med Ctr, Preston Robert Tisch Brain Tumor Ctr, Dept Neurosurg, Durham, NC USA
[14] Univ Calif Los Angeles, Dept Neurol, David Geffen Sch Med, Los Angeles, CA USA
[15] Fdn Med, Cambridge, MA USA
基金
美国国家卫生研究院;
关键词
HISTORICAL CONTROL DATA; REAL-WORLD EVIDENCE; SINGLE-ARM; ADJUVANT PACLITAXEL; ADJUSTMENT; SURVIVAL; RANDOMIZATION; TEMOZOLOMIDE; TRASTUZUMAB; BEVACIZUMAB;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Integration of external control data, with patient-level information, in clinical trials has the potential to accelerate the development of new treatments in neuro-oncology by contextualising single-arm studies and improving decision making (eg, early stopping decisions). Based on a series of presentations at the 2020 Clinical Trials Think Tank hosted by the Society of Neuro-Oncology, we provide an overview on the use of external control data representative of the standard of care in the design and analysis of clinical trials. High-quality patient-level records, rigorous methods, and validation analyses are necessary to effectively leverage external data. We review study designs, statistical methods, risks, and potential distortions in using external data from completed trials and real-world data, as well as data sources, data sharing models, ongoing work, and applications in glioblastoma.
引用
收藏
页码:E456 / E465
页数:10
相关论文
共 50 条
  • [31] Epidemiology of glioma: clinical characteristics, symptoms, and predictors of glioma patients grade I–IV in the the Danish Neuro-Oncology Registry
    Birthe Krogh Rasmussen
    Steinbjørn Hansen
    René J. Laursen
    Michael Kosteljanetz
    Henrik Schultz
    Bente Mertz Nørgård
    Rikke Guldberg
    Kim Oren Gradel
    Journal of Neuro-Oncology, 2017, 135 : 571 - 579
  • [32] Surgical treatment for insular gliomas. A systematic review and meta-analysis on behalf of the EANS neuro-oncology section
    Simon, Matthias
    Hagemann, Anne
    Gajadin, Sanjana
    Signorelli, Francesco
    Vincent, Arnaud J. P. E.
    BRAIN AND SPINE, 2024, 4
  • [33] Leveraging existing data to contextualize phase II clinical trial fi ndings in oncology
    Ray, E. M.
    Carey, L. A.
    Reeder-Hayes, K. E.
    ANNALS OF ONCOLOGY, 2020, 31 (12) : 1591 - 1593
  • [34] Epidemiology of glioma: clinical characteristics, symptoms, and predictors of glioma patients grade I-IV in the the Danish Neuro-Oncology Registry
    Rasmussen, Birthe Krogh
    Hansen, Steinbjorn
    Laursen, Rene J.
    Kosteljanetz, Michael
    Schultz, Henrik
    Norgard, Bente Mertz
    Guldberg, Rikke
    Gradel, Kim Oren
    JOURNAL OF NEURO-ONCOLOGY, 2017, 135 (03) : 571 - 579
  • [35] The design and evaluation of hybrid controlled trials that leverage external data and randomization
    Ventz, Steffen
    Khozin, Sean
    Louv, Bill
    Sands, Jacob
    Wen, Patrick Y.
    Rahman, Rifaquat
    Comment, Leah
    Alexander, Brian M.
    Trippa, Lorenzo
    NATURE COMMUNICATIONS, 2022, 13 (01)
  • [36] Precision Oncology Clinical Trials: A Systematic Review of Phase II Clinical Trials with Biomarker-Driven, Adaptive Design
    Ha, Hyerim
    Lee, Hee Yeon
    Kim, Jee Hyun
    Kim, Do Yeun
    An, Ho Jung
    Bae, SeungJin
    Park, Hye-sung
    Kang, Jin Hyoung
    CANCER RESEARCH AND TREATMENT, 2024, 56 (04): : 991 - 1013
  • [37] Gliomatosis cerebri (GC) or GC-like? A picture to be reconsidered in neuro-oncology based on large retrospective analysis of GC series
    Anghileri, Elena
    Schettino, Carla
    Pollo, Bianca
    Farinotti, Mariangela
    Silvani, Antonio
    Paterra, Rosina
    Patane, Monica
    DiMeco, Francesco
    Bruzzone, Maria Grazia
    Eoli, Marica
    Cuccarini, Valeria
    NEUROLOGICAL SCIENCES, 2020, 41 (08) : 2111 - 2120
  • [38] Impact of social factors on outcomes following pediatric neuro-oncology surgery in the United States: a systematic review and meta-analysis
    Kumar, Neerav
    Xu, Grace Dydian
    Lathrop, Cooper
    Shi, Jeffrey
    Kumar, Abhinav
    Winston, Graham
    Quraishi, Danyal Ahmed
    Akosman, Izzet
    Larsen, Alexandra Giantini
    Hussain, Ibrahim
    Hoffman, Caitlin
    NEUROSURGICAL REVIEW, 2025, 48 (01)
  • [39] Neuro-Oncology Practice Clinical Debate: Early treatment or observation for patients with newly diagnosed oligodendroglioma and small-volume residual disease
    Fogh, Shannon E.
    Boreta, Lauren
    Nakamura, Jean L.
    Johnson, Derek R.
    Chi, Andrew S.
    Kurz, Sylvia C.
    NEURO-ONCOLOGY PRACTICE, 2021, 8 (01) : 11 - 17
  • [40] Design for immuno-oncology clinical trials enrolling both responders and nonresponders
    Xu, Zhenzhen
    Zhu, Bin
    Park, Yongsoek
    STATISTICS IN MEDICINE, 2020, 39 (27) : 3914 - 3936